The CDK 4/6 inhibitor ribociclib has activity in the treatment of inoperable desmoid tumor. A case report

References

• Heiskanen I, Jarvinen HJ. Occurrence of desmoid tumours in familial adenomatous polyposis and results of treatment. Int J Colorectal Dis. 1996;11:157–162.
   PubMed Web of Science ®Google Scholar
• Koskenvuo L, Pitkaniemi J, Rantanen M, et al. Impact of screening on survival in familial adenomatous polyposis. J Clin Gastroenterol. 2016;50:40–44.
   PubMed Web of Science ®Google Scholar
• Yao X, Corbett T, Gupta AA, et al. A systematic review of active treatment options in patients with desmoid tumours. Curr Oncol. 2014;21:613–629.
   Web of Science ®Google Scholar
• ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2014;25:iii102–iii112.
   PubMed Web of Science ®Google Scholar
• Abraham J, Coleman R, Elias A, et al. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG). Breast Cancer Res Treat. 2018;171:11–20.
   PubMed Web of Science ®Google Scholar
• Dickson MA, Tap WD, Keohan ML, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. JCO. 2013;131:2024–2028.
   Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247.
   PubMed Web of Science ®Google Scholar
• Fiore M, Coppola S, Cannell AJ, et al. Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk. Ann Surg. 2014;259:973–978.
   PubMed Web of Science ®Google Scholar
• Santos GA, Cunha IW, Rocha RM, et al. Evaluation of estrogen receptor alpha, estrogen receptor beta, progesterone receptor, and cKIT expression in desmoids tumors and their role in determining treatment options. Biosci Trends. 2010;4:25–30.
   PubMed Web of Science ®Google Scholar
• Mignemi NA, Itani DM, Fasig JH, et al. Signal transduction pathway analysis in desmoid-type fibromatosis: transforming growth factor-beta, COX2 and sex steroid receptors. Cancer Sci. 2012;103:2173–2180.
   PubMed Web of Science ®Google Scholar
• Brooks MD, Ebbs SR, Colletta AA, et al. Desmoid tumours treated with triphenylethylenes. Eur J Cancer. 1992;28A:10148.
   Web of Science ®Google Scholar
• Fiore M, Colombo C, Radaelli S, et al. Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis. Eur J Cancer. 2015;51:2800–2807.
   PubMed Web of Science ®Google Scholar
• Bocale D, Rotelli MT, Cavallini A, et al. Anti-oestrogen therapy in the treatment of desmoid tumours: a systematic review. Colorectal Dis. 2011;13:e388–e395.
   PubMed Web of Science ®Google Scholar
• Skapek SX, Anderson JR, Hill DA, et al. Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children’s Oncology Group (COG) phase II study. Pediatr Blood Cancer. 2013;60:1108–1112.
   PubMed Web of Science ®Google Scholar
• Bauernhofer T, Stoger H, Schmid M, et al. Sequential treatment of recurrent mesenteric desmoid tumor. Cancer 1996;77:1061–1065.
   PubMed Web of Science ®Google Scholar
• Wilcken N, Tattersall MH. Endocrine therapy for desmoid tumors. Cancer. 1991;68:1384–1388.
   PubMed Web of Science ®Google Scholar
• Debled M, Le Loarer F, Callonnec F, et al. Complete response to exemestane in a patient with a desmoid tumor. Future Oncol. 2012;8:483–486.
   PubMed Web of Science ®Google Scholar
• Ahlin C, Lundgren C, Embretsen-Varro E, et al. High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers. Breast Cancer Res Treat. 2017;164:667–678.
   PubMed Web of Science ®Google Scholar
• Xu XL, Chen SZ, Chen W, et al. The impact of cyclin D1 overexpression on the prognosis of ER-positive breast cancers: a meta-analysis. Breast Cancer Res Treat. 2013;139:329–339.
   PubMed Web of Science ®Google Scholar
• Thangavel C, Dean JL, Ertel A, et al. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011;18:333–345.
   PubMed Web of Science ®Google Scholar
• Spazzapan S, Conte P, Simoncini E, et al. C11Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib. + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC). Ann Oncol. 2017;28:mdx424.010–mdx424.010.
   Web of Science ®Google Scholar
• Saito T, Oda Y, Tanaka K, et al. beta-catenin nuclear expression correlates with cyclin D1 overexpression in sporadic desmoid tumours. J Pathol. 2001;195:222–228.
   PubMed Web of Science ®Google Scholar
• Jilong Y, Jian W, Xiaoyan Z, et al. Analysis of APC/beta-catenin genes mutations and Wnt signalling pathway in desmoid-type fibromatosis. Pathology 2007;39:319–325.
   PubMed Web of Science ®Google Scholar
• Colombo C, Foo WC, Whiting D, et al. FAP-related desmoid tumors: a series of 44 patients evaluated in a cancer referral center. Histol Histopathol. 2012;27:641–649.
   PubMed Web of Science ®Google Scholar
• Spring LM, Zangardi ML, Moy B, et al. Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4/6 inhibitors in breast cancer: practical considerations and recommendations. Oncologist. 2017;22:1039–1048.
   PubMed Web of Science ®Google Scholar
• Yin CC, Glassman AB, Lin P, et al. Morphologic, cytogenetic, and molecular abnormalities in therapy-related acute promyelocytic leukemia. Am J Clin Pathol. 2005;123:840–848.
   PubMed Web of Science ®Google Scholar
• Kassem L, Shohdy KS, Lasheen S, et al. Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. Breast Cancer. 2018;25:17–27.
   PubMed Web of Science ®Google Scholar